Advertisement
Advertisement
NVCR
NovoCure Limited Ordinary Shares
10.13
USDSponsored
+0.04
+0.43%
Feb 06, 16:00 UTC -5
Closed
After-Market
10.21
+0.07
+0.72%
NVCR Earnings Reports
Positive Surprise Ratio
NVCR beat 23 of 40 last estimates.
57%
Next Report
Date of Next Report
Feb 26, 2026
Estimate for Q4 25 (Revenue/ EPS)
$177.68M
/-$0.41
Implied change from Q3 25 (Revenue/ EPS)
+6.27%
/+24.24%
Implied change from Q4 24 (Revenue/ EPS)
+10.18%
/-32.79%
NovoCure Limited Ordinary Shares earnings per share and revenue
On Oct 30, 2025, NVCR reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.42 USD, resulting in a 23.15% surprise. Revenue reached 167.20 million, compared to an expected 162.37 million, with a 2.98% difference. The market reacted with a -4.90% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.41 USD, with revenue projected to reach 177.68 million USD, implying an increase of 24.24% EPS, and increase of 6.27% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were NovoCure Limited Ordinary Shares's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, NovoCure Limited Ordinary Shares reported EPS of -$0.33, beating estimates by 23.15%, and revenue of $167.20M, 2.98% above expectations.
How did the market react to NovoCure Limited Ordinary Shares's Q3 2025 earnings?
The stock price moved down -4.9%, changed from $13.48 before the earnings release to $12.82 the day after.
When is NovoCure Limited Ordinary Shares expected to report next?
The next earning report is scheduled for Feb 26, 2026.
What are the forecasts for NovoCure Limited Ordinary Shares's next earnings report?
Based on 10
analysts, NovoCure Limited Ordinary Shares is expected to report EPS of -$0.41 and revenue of $177.68M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement